INDV · Indivior Pharmaceuticals, Inc.

Track INDV — free

$34.87 -0.43 (-1.22%) At close · Aug 28

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$4.12B

118.01M

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 3, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Weak Sentiment Very Bullish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −2%

below

Price vs 50-day avg −11%

below

RSI (14) 29

oversold

MACD trend Negative

52-week position 64%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −13%

trailing

6-month return +7%

trailing

YTD return −3%

this year

Relative strength −6%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $39 › 200d $36 — 50d above 200d

Institutional flow Accumulating

+15% holders QoQ · +90 funds added

Insider flow Accumulating

Net +$108.0K over 90 days · 0% sells

Short interest Falling

8.85% of float · ▼ -4.0% MoM · 3.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

337 holders — near 1-yr high, broad support

Squeeze score 53

elevated · 0–100

Fundamentals

Strong

Revenue growth +4%

Y/Y

Gross margin 80%

contracting

EPS growth +3180%

Y/Y

Free cash flow $-93.0M

Valuation P/E 12.5

below peers

Buyback $100.0M

remaining

Quant / Vol

risk profile

Moderate

Volatility 37%

annualized · 1-yr

Max drawdown −21%

past year

ATR 3.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Aug 3, 2026

Full-year 2026

Adjusted EBITDA Non-GAAP Initiated $700M – $740M

2026

Non-GAAP operating expenses Non-GAAP up to $450M

Cash flow from operations $420M

Prior guidance period ended · from the 8-K filed Oct 30, 2025

Non-GAAP SG&A · FY 2025 $510M – $520M

Adjusted EBITDA · FY 2025 $400M – $420M

Non-GAAP R&D · FY 2025 $75M – $80M

Total Net Revenue · FY 2025 $1.18B – $1.22B

Non-GAAP Operating Expenses · FY 2025 $585M – $600M

SUBLOCADE Net Revenue · FY 2025 $825M – $845M

Guided vs delivered · last 3 settled

Total Net Revenue FY 2025

guided $1.18B – $1.22B

guided $1.18B – $1.22B $1.24B Beat +3.3%

Total company full-year 2023 net revenue full-year 2023

guided $1.03B – $1.09B

guided $1.03B – $1.09B $1.09B Beat +3.1%

Total net revenue fiscal year 2022

guided $890M – $915M

guided $890M – $915M $901M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−2% Neutral

Price vs 50-day avg

−11% Bearish

RSI (14)

29 Neutral

MACD trend

Negative Bearish

52-week position

64% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $39 › 200d $36 — 50d above 200d

Institutional flow Accumulating

+15% holders QoQ · +90 funds added

Insider flow Accumulating

Net +$108.0K over 90 days · 0% sells

Short interest Falling

8.85% of float · ▼ -4.0% MoM · 3.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

337 holders — near 1-yr high, broad support

Price context

position in its 52-week range

Range low $23 Now $35 · 64% Range high $42

vs 200-day avg -2% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adj. EBITDA Margin non-GAAP	54%	Q2 2026	—

Adjusted EBITDA non-GAAP	$350M	Six Months Ended June 30, 2026	—

Average share repurchase price	$37.52	Q2 2026	—
Convertible senior notes issued	$500M	2026	—
CRM enrollments per month	1,300	Q2 2026	—
dispense unit volume growth	18%	Q2 2026	—
Growth in new patient starts	27%	Q2 2026 vs Q2 2025	—
HCPs with 5+ SUBLOCADE Patients growth (YoY)	18%	Q2 2026	—
New patient starts	32,816	Q2 2026	—
Non-GAAP diluted earnings per share non-GAAP	$2.1	Six Months Ended June 30, 2026	—

Non-GAAP net income non-GAAP	$266M	Six Months Ended June 30, 2026	—

Non-GAAP operating expenses non-GAAP	$229M	Six Months Ended June 30, 2026	—

patients in the U.S. have been prescribed SUBLOCADE since launch	545,000	As of June 30, 2026	—
People utilizing the FASTP physician locator	34,000	Q2 2026	—
Share repurchases	$175M	Q2 2026	—
SUBLOCADE Dispense Growth (YoY)	18%	Q2 2026	—
SUBLOCADE Net Revenue	$253M	FY2026 Q2	+21.1%

SUBLOCADE Net Revenue growth	21%	Q2 2026	—
SUBLOCADE share of U.S. LAI category	76%	TTM Q2 2026	—

Term loan repaid	$333M	2026	—
Total SUBLOCADE net revenue	$486M	Six Months Ended June 30, 2026	—

TTM SUBLOCADE Patients growth (YoY)	17%	TTM Q2 2026	—
U.S. SUBLOCADE net revenue	$238M	Q2 2026	—
Cash and investments	$201M	as of March 31, 2026	—
Non-GAAP Gross Margin non-GAAP	88%	Q1 2026	—
Non-GAAP Gross Profit non-GAAP	$278M	Q1 2026	—
Share of voice with core search words	90%	Q1 2026	—
Share repurchase program remaining authorization	$275M	as of April 30, 2026	—
Shares repurchased	4M	Q1 2026	—
U.S. SUBLOCADE dispense unit volume growth	20%	Q1 2026	—
Adjusted Leverage non-GAAP	0.7	FY 2025	—
HCPs with 5+ SUBLOCADE Patients	14%	Q4 2025	—
Net Debt	$283M	FY 2025	—
Shares used in computing diluted non-GAAP earnings per share non-GAAP	128M	FY 2025	—
SUBLOCADE dispense unit growth	7%	FY 2025	—
SUBLOCADE Net Revenue CAGR	23%	FY 2025	—
Total SUBLOCADE dispense unit growth	7%	FY 2025	—
TTM SUBLOCADE Patients	12%	Q4 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INDV Indivior Pharmaceuticals, Inc. this stock	$4.12B	-2.8%	+4.3%	12.5	8.9%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$57.59B	+15.7%	—	—	0.1%
GALDY Galderma Group AG/ADR	$49.38B	+2.2%	—	—	0.0%
HLN Haleon plc	$44.46B	+0.0%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

337

% held: 105.6%
Net QoQ: -3.5M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

321

View

Short & Settlement

Short Interest Falling

Shares short

10.4M

Days to cover: 3.3d
Change: -430.4K sh

View

Short Volume

Short vol %

26%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

12.0K

Value: $481.4K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

58.2%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$108.0K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$1.2B

Net income (FY): $210.0M
EPS diluted: $1.64

View

Buybacks

Authorized

$175.0M

Remaining: $100.0M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 3, 2026
This year: 17

View

Proposed Sales

Value

$764.6K

Shares: 18.6K
Filed: Jul 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
INDV	-5.4%	-12.9%	+7.0%	-12.9%	-2.8%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	-5.9%	-15.8%	-6.5%	-15.8%	-15.6%

Capital returns

Buyback program · as of Jun 30, 2026

Authorized

$175.00M

Spent (derived)

$75.00M

Remaining

$100.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 272 filings 271 filers Visit website Investor relations

INDV · Indivior Pharmaceuticals, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns